Skip to main content

09-12-2019 | Haematology | Video

ASH 2019 | Mosunetuzumab offers an option beyond CAR T-cell therapy in NHL

Stephen Schuster gives the latest findings on mosunetuzumab showing durable response in poor prognosis patients with non-Hodgkin lymphoma (5:11). 

Funding for independent interviews at ASH 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

This study was supported by Genentech, a member of the Roche group

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits